The Royal Society Enterprise Fund, a quasi-corporate venturing fund, has joined a consortium investing £2.75m ($5m) in OrganOx, a UK-based medical device manufacturer to increase the number of human livers available for transplant.
OrganOx was spun out of the University of Oxford by Isis Innovation in 2008 and had venture capital firms Oxford Technology Management and Technikos as its initial investors.
Last month, the Royal Society fund joined a £1.6m round backing Novacem, a carbon-negative cement company, alongside contruction company Laing O’Rourke.